Intermittent Preventive Treatment of Malaria in Pregnancy with Mefloquine in HIV-Negative Women: A Multicentre Randomized Controlled Trial

Raquel González, Ghyslain Mombo-Ngoma, Smaïla Ouédraogo et al.
PLoS Med 11(9): e1001733 (23 September 2014)

17 pp. 1.2 MB:
http://www.plosmedicine.org/article/fetchObject.action?
uri=info%3Adoi%2F10.1371%2Fjournal.pmed.1001733&representation=PDF
Pic 003

Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended by WHO to prevent malaria in African pregnant women. The spread of SP parasite resistance has raised concerns regarding long-term use for IPT. Mefloquine (MQ) is the most promising of available alternatives to SP based on safety profile, long half-life, and high efficacy in Africa. The authors found that MQ recipients had less clinical malaria than SP recipients, and the pregnancy outcomes and safety profile were similar. MQ had poorer tolerability even when splitting the dose over two days. These results do not support a change in the current IPTp policy.

(Visited 23 times, 1 visits today)
This entry was posted in Essential Medicines, General, Malaria, Maternal & Child Health. Bookmark the permalink.